Tetra Bio-Pharma Comments on Recent Trading Activity at the Request of IIROC
July 05 2019 - 04:42PM
Tetra Bio-Pharma Inc. ("
Tetra" or
the "
Corporation") a bio-pharmaceutical
multifaceted corporation with its primary focus in
cannabinoid‑based drug discovery and development (TSX-V: TBP)
(OTCQB: TBPMF), wishes to confirm that the Company's management is
unaware of any material change in the Company's operations that
would account for the recent increase in market activity.
About Tetra Bio-Pharma
Inc.
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is
a biopharmaceutical multifaceted corporation with its primary focus
in cannabinoid-based drug discovery and development with a clinical
trial program aimed at bringing novel drugs and treatments to
patients and their healthcare providers. Tetra Bio-Pharma’s
subsidiary, Tetra Natural Health, also focuses on the development
and commercialization of natural health and self-care products as
well as the sale of its hemp energy drinks.
For more information visit:
www.tetrabiopharma.com and www.tetranaturalhealth.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Forward-looking statementsSome
statements in this release may contain forward-looking information.
All statements, other than of historical fact, that address
activities, events or developments that the Company believes,
expects or anticipates will or may occur in the future (including,
without limitation, statements regarding potential acquisitions and
financings) are forward-looking statements. Forward-looking
statements are generally identifiable by use of the words "may",
"will", "should", "continue", "expect", "anticipate", "estimate",
"believe", "intend", "plan" or "project" or the negative of these
words or other variations on these words or comparable terminology.
Forward-looking statements are subject to a number of risks and
uncertainties, many of which are beyond the Company's ability to
control or predict, that may cause the actual results of the
Company to differ materially from those discussed in the
forward-looking statements. Factors that could cause actual results
or events to differ materially from current expectations include,
among other things, without limitation, the inability of the
Company to obtain sufficient financing to execute the Company's
business plan; competition; regulation and anticipated and
unanticipated costs and delays, the success of the Company's
research and development strategies, including the products
mentioned in this release, the applicability of the discoveries
made therein, the successful and timely completion and
uncertainties related to the regulatory process including the
applications for Orphan Drug Designation, the timing of clinical
trials, the timing and outcomes of regulatory or intellectual
property decisions and other risks disclosed in the Company's
public disclosure record on file with the relevant securities
regulatory authorities. Although the Company has attempted to
identify important factors that could cause actual results or
events to differ materially from those described in forward-looking
statements, there may be other factors that cause results or events
not to be as anticipated, estimated or intended. Readers should not
place undue reliance on forward-looking statements. While no
definitive documentation has yet been signed by the parties and
there is no certainty that such documentation will be signed. The
forward-looking statements included in this news release are made
as of the date of this news release and the Company does not
undertake an obligation to publicly update such forward-looking
statements to reflect new information, subsequent events or
otherwise unless required by applicable securities legislation.
For further information, please contact Tetra Bio-Pharma
Inc.Robert (Bob) Bechard
Executive Vice President, Corporate Development and Licensing
514-817-2514 Investors@tetrabiopharma.com
Media
Contact energi PR Carol Levine
Carol.Levine@energipr.com 514-288-8500 ext. 226 |
Stephanie Engel
stephanie.engel@energipr.com 416-425-9143 ext.
209 |
Tetra Bio Pharma (TSXV:TBP)
Historical Stock Chart
From Feb 2024 to Mar 2024
Tetra Bio Pharma (TSXV:TBP)
Historical Stock Chart
From Mar 2023 to Mar 2024